Early treatment with Gilead Sciences Inc.’s remdesivir kept high-risk Covid-19 patients out of the hospital in a late-stage international trial that supports administering the medicine to individuals recovering at home.
A three-day course of the injectable antiviral, also known as Veklury, was associated with an 87% reduction in hospitalizations in a randomized, placebo-controlled trial involving 562 patients, Gilead said in a statement Wednesday. The data are slated for release at a virtual medical meeting on Sept. 29.
